NPP (Nandrolone Phenylpropionate): Short-Ester Nandrolone, Progestogenic Activity, and Bloodwork Guide

Nandrolone phenylpropionate in brief

Three numbers frame nandrolone phenylpropionate: what the ester comparison measured, what the hormone did to lean mass across every randomised trial, and what it did to the axis in the men who took it.

Every figure is taken from the abstracts of the twenty-one papers at the end. NPP, nandrolone phenylpropionate and nandrolone decanoate are named because the papers name them; no dose, schedule or cycle is given here.

What this nandrolone phenylpropionate profile covers

What is NPP? Nandrolone phenylpropionate, the ester and the 19-nor structure

What is the npp steroid, chemically: nandrolone, which is testosterone without the carbon-19 methyl group, attached to a phenylpropionate ester so that it can be injected in oil and released over days rather than hours. The hormone that reaches the blood is nandrolone, identical to what Deca-Durabolin releases; the ester decides how fast it arrives and how long it stays. That is the whole of the nandrolone phenylpropionate vs deca difference, and it was measured once in men (PMID 9103484).

The 19-nor structure is what makes nandrolone different from testosterone at the receptors. In the classic binding study, nandrolone bound the androgen receptor in skeletal muscle more strongly than testosterone, second only to the reference ligand (PMID 6539197). In human cell bioassays it also activated the progesterone receptor at nanomolar to picomolar concentrations, an effect abolished by antiprogestins and not by antiandrogens, where testosterone needed a thousand-fold higher concentration to do the same (PMID 9228646). Nandrolone phenylpropionate delivers a hormone that is both a strong androgen and a progestogen.

The estrogen side is more complicated than the forum version. Nandrolone is described in the cardiac trial as a non-aromatisable pure androgen (PMID 17223994), but in human breast cancer cells both nandrolone and stanozolol induced aromatase expression and estradiol production in a dose-dependent way, more so with IGF-I (PMID 22906881). Whether that happens in a man on nandrolone phenylpropionate has not been measured; what has been measured is what the hormone does to LH, testosterone and sexual function, in the hormones section below. How injectables differ from orals as a class is on injectable vs oral steroids.

What is measured on nandrolone, and in whom

The npp steroid itself has two human studies on nandrolone phenylpropionate. Nandrolone as a hormone has dozens, because the decanoate was a licensed drug for anemia and wasting. The table keeps the ester data, the hormone data, the cell data and the class data apart.

Read the weight column first. The ester has one kinetic trial and one surgical pilot. The hormone has a real randomised record: it builds lean mass in people who are losing it, it lowers HDL in some populations and not others, it leaves the heart alone over four weeks, and it shuts the axis fast and reopens it slowly. That is the evidence base for the npp steroid, and the rest of this page stays inside it.

Nandrolone phenylpropionate vs deca: what the ester comparison found

The nandrolone phenylpropionate vs deca question has exactly one human answer, and it is a good one. Twenty-three healthy men were randomised to a single intramuscular injection of nandrolone phenylpropionate or nandrolone decanoate in four millilitres of arachis oil into the gluteal muscle, or to nandrolone decanoate in one millilitre into the gluteal or deltoid muscle, and were sampled for 32 days. Plasma nandrolone was influenced by the ester and the injection site, with higher and earlier peaks after the phenylpropionate; testosterone suppression was most rapid but briefest after the phenylpropionate and most sustained after the small-volume gluteal decanoate; and inhibin followed volume and site (PMID 9103484).

Three things follow for anyone weighing nandrolone phenylpropionate vs deca. First, the hormone is the same, so the receptor effects, the progestogenic activity and the lipid and axis effects below belong to both esters. Second, the short ester means a faster rise, a faster fall, and a faster return of the axis after the last injection, which is the one real advantage of nandrolone phenylpropionate and the reason the trial found its suppression briefest. Third, where and how much you inject changed the curve as much as which ester you chose, which no forum comparison mentions.

The long ester in its own trials is on deca-durabolin; the half-life logic for testosterone esters, which is the same logic, is on testosterone cypionate.

Lean mass on nandrolone: what twenty randomised trials found

Nandrolone phenylpropionate has no lean-mass trial of its own, so the muscle data come from the decanoate, which delivers the same hormone more slowly. The 2026 meta-analysis pooled 20 randomised placebo-controlled trials in adults: nandrolone decanoate raised lean soft tissue by a mean 1.59 kg across 11 trials with zero heterogeneity, did not change fat mass across 11 trials, did not change handgrip strength across 12, and had inconsistent effects on bone; the authors rated the certainty low and noted that the gain in tissue was not matched by function (PMID 41936385).

The single trials show where the number comes from. In 79 dialysis patients randomised in a two-by-two design, 12 weeks of weekly nandrolone decanoate raised lean body mass by 3.1 kg, resistance exercise alone did not raise it, and quadriceps cross-sectional area rose with both in an additive way; exercise, not the drug, improved self-reported physical function (PMID 16825332). In chronic kidney disease overall, four trials pooled gave 2.63 kg (PMID 42714768).

In 303 HIV-positive men with wasting, nandrolone added 1.34 kg of fat-free mass and 1.48 kg of weight against placebo and 1.00 kg of weight against testosterone (PMID 16494628); in a second HIV trial it added 1.6 kg of lean mass against 0.4 on placebo and matched growth hormone with fewer adverse effects (PMID 15914526). In burns it preserved lean mass and nitrogen balance (PMID 34172326).

What a lifter should take from this is limited and specific. The only nandrolone phenylpropionate performance data are in rats: trained animals given nandrolone phenylpropionate ran 41 percent longer in a submaximal endurance test than trained animals on saline, with no gain in sedentary animals and no further gain in sprint speed (PMID 8531609). Every human lean-mass number above came from a patient losing muscle, over 12 weeks, on the long ester. The one human nandrolone phenylpropionate trial in a non-wasting setting, 54 men before prostatectomy, measured postoperative symptom scores, not muscle (PMID 18821287). The class benchmark for a healthy trained man remains the testosterone ester dose-response on testosterone cypionate.

Lipids, cholesterol synthesis and the heart on nandrolone

The lipid data behind nandrolone phenylpropionate disagree with each other in an instructive way. In 30 HIV-infected men randomised to a high weekly dose of nandrolone decanoate with or without resistance training for 12 weeks, HDL cholesterol fell by 8.7 and 10.6 milligrams per decilitre in the two groups, with the large HDL2 subfractions falling and the small HDL3 rising, while triglycerides and lipoprotein(a) fell and insulin sensitivity did not worsen (PMID 12388173). In 16 bodybuilders randomised double-blind to eight weeks of nandrolone decanoate, cholesterol, HDL, HDL2, HDL3 and apolipoproteins did not change at four or eight weeks or six weeks after withdrawal, while lipoprotein(a) fell (PMID 15155420).

The mechanism is measurable within days. In 11 healthy men given a single injection of nandrolone decanoate, the mRNA of HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis, was raised in 80 percent of them by day 4, and total cholesterol and apolipoprotein B were significantly higher by day 14 (PMID 26370185). In 56 gym users followed for a year after stopping, HDL was significantly higher and LDL lower for six months after cessation, and the profile normalised within six months while the axis in some men did not (PMID 21884791). Nandrolone moves cholesterol in the wrong direction quickly and back in the right direction within months; what a stack does is another matter, on do steroids raise cholesterol.

The heart was measured directly. In 30 healthy young men randomised double-blind to weekly testosterone, weekly nandrolone decanoate or placebo for four weeks, left and right ventricular function, cardiac output and vascular resistance stayed within reference ranges and were not altered by either androgen; the minor changes that did appear, a larger end-systolic diameter and a higher filling pressure, were in the testosterone arm only (PMID 17223994). Four weeks is the caveat: the cohort of long-term users of the class had a lower ejection fraction, 50 against 54 percent, and coronary disease in 17 percent (PMID 35460300).

Hormones, libido and recovery: the axis on nandrolone

Nandrolone phenylpropionate suppresses the axis fast. In the ester trial, testosterone suppression after nandrolone phenylpropionate was the most rapid of the four regimens and also the briefest (PMID 9103484). In 11 healthy men, LH and FSH were significantly suppressed four days after one injection of the decanoate, with a small transient fall in SHBG (PMID 26370185). In 76 dialysis patients, those on anabolic steroids including nandrolone decanoate had testosterone of 205 against 450 ng/dl in those without, with no difference in gonadotropins or prolactin (PMID 2805460).

Recovery is where the long ester and the short ester part, and where the record is worst. In 56 gym users followed after stopping intramuscular steroids, LH and FSH stayed suppressed for several months and in some men for a full year; the nandrolone metabolite 19-norandrosterone remained detectable for months and its level tracked the gonadotropins, while testosterone abuse was detectable for only weeks (PMID 21884791). The kinetic argument for nandrolone phenylpropionate is that a short ester clears sooner and the axis restarts sooner, which the ester trial supports over 32 days (PMID 9103484); no study has measured recovery after a course of nandrolone phenylpropionate.

The nandrolone phenylpropionate libido question, the one the forums call by a nickname, has a measurement that points the other way. In the randomised HIV trial, nandrolone was associated with greater improvement in sexual function than placebo over 12 weeks, alongside better perceived health than growth hormone (PMID 15914526). Prolactin, the usual explanation offered, was not different in dialysis patients on nandrolone from those off it (PMID 2805460).

What is measured on the progestogenic side is the receptor: nandrolone activates the progesterone receptor at nanomolar concentrations in human cells (PMID 9228646). What that does to a man with low testosterone from suppression is the plausible mechanism, and the bloodwork below tests it in one person. The class data on desire and function are on libido on steroids; recovery is on when to start PCT.

Nandrolone phenylpropionate side effects by the evidence

Nandrolone phenylpropionate side effects are the side effects of nandrolone arriving faster. The table gives each with the strongest source that exists and says which kind of source it is.

The honest summary of nandrolone phenylpropionate side effects is that the npp steroid shuts the axis within days, moves cholesterol synthesis within days, activates the progesterone receptor at concentrations a person reaches, and, in the one trial that asked, did not worsen sexual function. The short ester changes when these start and stop, not whether they happen.

Nandrolone phenylpropionate bloodwork: eight markers

Because the single-injection data show the axis and cholesterol synthesis moving within four days (PMID 26370185), the first panel on the npp steroid should be early, and the last should be late, since recovery is measured in months (PMID 21884791).

Timing follows the ester: nandrolone phenylpropionate peaks and clears faster than the decanoate (PMID 9103484), so a panel drawn in the first two weeks catches the axis and ApoB moving, and a panel two to three months after the last injection tests whether recovery has begun. The baseline set is on blood tests before steroids.

Five mistakes people make with nandrolone phenylpropionate

Each of these comes from treating the ester as the drug.

1. Expecting nandrolone phenylpropionate to behave differently from deca at the receptor. The hormone is the same; the ester trial changed peaks and timing, not what nandrolone does once it arrives (PMID 9103484).

2. Reading the short ester as a short recovery. Suppression starts within four days (PMID 26370185) and in users of the class lasted months to a year after stopping (PMID 21884791). The ester sets the start of recovery, not its length.

3. Blaming libido on prolactin without measuring it. Prolactin was not raised in patients on nandrolone (PMID 2805460), and sexual function improved against placebo in the trial that measured it (PMID 15914526). Suppressed testosterone is the measured variable.

4. Treating eight clean weeks as a lipid pass. Bodybuilders on nandrolone alone showed no HDL change (PMID 15155420), but cholesterol synthesis rises by day 4 (PMID 26370185), HDL fell in HIV men (PMID 12388173), and stacks cut HDL by 60 percent (PMID 15155420).

5. Expecting strength from the lean mass number. Across 12 randomised trials, handgrip did not change while lean tissue rose 1.59 kg (PMID 41936385). Tissue and function are different endpoints, and the trials measured both.

Verdict: a well-measured hormone on a lightly measured ester

Nandrolone phenylpropionate, after the papers rather than the forums, is nandrolone with a short ester: higher and earlier peaks and the fastest, briefest testosterone suppression in the one human ester trial (PMID 9103484), delivering a hormone that binds the muscle androgen receptor above testosterone (PMID 6539197), activates the progesterone receptor at nanomolar concentrations (PMID 9228646), adds 1.59 kg of lean tissue without strength across 20 randomised trials (PMID 41936385), suppresses LH and FSH within four days (PMID 26370185), raises cholesterol synthesis within four days (PMID 26370185), leaves the heart unchanged over four weeks (PMID 17223994), and in gym users kept the axis down for months to a year (PMID 21884791).

The nandrolone phenylpropionate side effects that matter are the ones a panel catches early and late: LH, FSH and testosterone in the first two weeks and again months after the last injection; HDL and ApoB; estradiol and prolactin to test the claims; hematocrit and blood pressure. Everything upstream of that panel is on the PED side effects hub and on blood tests before steroids; the same hormone on the long ester, with its own trials, is deca-durabolin.